ReviewFrontiers in oncology2025
The role of MYEOV gene: a review and future directions.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- mRNA and microRNA Expression Profile of Corneal and Conjunctival Impression Cytology Samples.Biology · 2026Article
- Mechanisms of circular RNAs in diabetic cardiomyopathy: biological characteristics and clinical prospects.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overexpressed gene MYEOV in multiple myeloma, as an oncogene, has been widely recognized for its high expression levels in various malignant tumors. MYEOV plays a significant role in multiple malignancies, particularly in diseases such as multiple myeloma, breast cancer, lung cancer, pancreatic cancer, and esophageal cancer. The presence of the open reading frame of MYEOV in humans and other primates suggests its potential protein-coding capacity, although direct evidence of functional MYEOV protein is currently lacking. The role of MYEOV in various tumors is not limited to its direct effects as an oncogene; it also includes its complex role in tumor cell signaling pathways and its ability to participate in miRNA regulatory networks as a competing endogenous RNA (ceRNA). Studies have shown that MYEOV may affect the expression of cancer-related genes through enhancer activity. This article aims to provide a comprehensive review of the role of MYEOV, its involvement in signaling pathways in tumor cells, and the latest advancements in MYEOV-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.